Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia.

@article{Kantarjian2006SurvivalBW,
  title={Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia.},
  author={Hagop M Kantarjian and Moshe Talpaz and Susan M O'Brien and Daniel P. Jones and Francis J Giles and Guillermo Garcia-Manero and Stefan H Faderl and Farhad Ravandi and Mary Beth Rios and Jianqin Shan and Jorge E. Cortes},
  journal={Blood},
  year={2006},
  volume={108 6},
  pages={1835-40}
}
A survival benefit for imatinib mesylate versus interferon-alpha therapy could not be demonstrated in the randomized study in newly diagnosed Philadelphia chromosome (Ph)-positive chronic-phase chronic myelogenous leukemia (CML) due to the high rate of crossover (90%) from interferon-alpha to imatinib mesylate within a year of study entry. We compared survival in 279 patients with newly diagnosed CML treated with imatinib mesylate at our institution (2000-2004) to 650 patients treated with… CONTINUE READING